It has been postulated that the generation of a CAR directed against CD126 (IL-6 receptor), an antigen that is broadly present on the surface of many hematologic and solid tumors (including MM, lymphoma, AML, pancreatic and prostate adenocarcinoma, non-small cell lung cancer, malignant melanoma, and many others), may be a solution to the extremely expensive production of CAR-T cells, which is partly due to the restricted use of each CAR construct for specific tumors. The gene discussed is IL6R; the disease is Miyoshi myopathy.